Status:
COMPLETED
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Breast Cancer
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Primary Objectives: 1. To assess the feasibility of mini-allogeneic Peripheral Blood Progenitor Cell (PBPC) transplantation in patients with recurrent or metastatic breast cancer. 2. To determine the...
Detailed Description
If tumors shrink by standard-dose chemotherapy, patients will receive moderate dose chemotherapy to prepare for the blood stem cell transplant. The drug fludarabine will be given by vein on days 1-5. ...
Eligibility Criteria
Inclusion
- Recurrent or residual metastatic breast carcinoma
- Zubrod performance status less than 2
- 18-60 years old
- Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor.
- No major organ dysfunction or active infection
Exclusion
- None
Key Trial Info
Start Date :
January 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00429572
Start Date
January 1 1998
End Date
May 1 2008
Last Update
August 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U.T.M.D. Anderson Cancer Center
Houston, Texas, United States, 77030